Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Serological response to influenza vaccination among adults hospitalized with community-acquired pneumonia.

Pratt CQ, Zhu Y, Grijalva CG, Wunderink RG, Mark Courtney D, Waterer G, Levine MZ, Jefferson S, Self WH, Williams DJ, Finelli L, Bramley AM, Edwards KM, Jain S, Anderson EJ.

Influenza Other Respir Viruses. 2019 Mar;13(2):208-212. doi: 10.1111/irv.12622. Epub 2018 Dec 17.

2.

Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.

Puig-Barberà J, Guglieri-López B, Tortajada-Girbés M, López-Labrador FX, Carballido-Fernández M, Mollar-Maseres J, Schwarz-Chavarri G, Baselga-Moreno V, Mira-Iglesias A, Díez-Domingo J; Valencia Hospital Network for the Study of Influenza, Respiratory Viruses Disease.

Vaccine. 2017 Dec 19;35(52):7331-7338. doi: 10.1016/j.vaccine.2017.10.100. Epub 2017 Nov 8.

3.

Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Petrie JG, Martin ET, Truscon R, Johnson E, Cheng CK, McSpadden EJ, Malosh RE, Lauring AS, Lamerato LE, Eichelberger MC, Ferdinands JM, Monto AS.

Vaccine. 2019 Feb 28;37(10):1284-1292. doi: 10.1016/j.vaccine.2019.01.055. Epub 2019 Feb 7.

PMID:
30738647
4.

Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada.

Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney J, McGeer A, Nichols MK, Powis J, Richardson D, Semret M, Stiver G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network and the Toronto Invasive Bacterial Diseases Network (TIBDN).

BMC Infect Dis. 2017 Dec 29;17(1):805. doi: 10.1186/s12879-017-2905-8.

5.
6.

Serological response of patients with influenza A (H1N1) pdm09-associated pneumonia: an observational study.

Angkasekwinai N, Kaewnapha B, Waywa D, Werarak P, Tongsai S, Chokephaibulkit K, Thamlikitkul V, Siritantikorn S.

PLoS One. 2013 Nov 27;8(11):e81436. doi: 10.1371/journal.pone.0081436. eCollection 2013.

7.

[Monitoring of influenza and other respiratory diseases causative agents in children, hospitalized with community-acquired pneumonia in 2012-2013 epidemic season].

Ostrovskaya OV, Kholodok GN, Ivakhnishina NM, Morozova NV, Karavyanskaya TN, Golubeva EM, Reznik VI, Savosina LV, Lebedeva LA, Prisyazhnyuk EN, Kozlov VK.

Zh Mikrobiol Epidemiol Immunobiol. 2015 Mar-Apr;(2):59-65. Russian.

PMID:
26016346
8.

Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.

King JP, McLean HQ, Meece JK, Levine MZ, Spencer SM, Flannery B, Belongia EA.

Vaccine. 2018 Feb 21;36(9):1214-1219. doi: 10.1016/j.vaccine.2018.01.016.

PMID:
29395525
9.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
10.

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.

Zerbini CA, Ribeiro Dos Santos R, Jose Nunes M, Soni J, Li P, Jain VK, Ofori-Anyinam O.

Braz J Infect Dis. 2017 Jan - Feb;21(1):63-70. doi: 10.1016/j.bjid.2016.10.003. Epub 2016 Nov 29.

11.

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

Hoschler K, Andrews NJ, Faust SN, Finn A, Pollard AJ, Snape MD, Walker WT, Zambon M, Miller E.

Clin Infect Dis. 2014 Jan;58(2):181-7. doi: 10.1093/cid/cit692. Epub 2013 Oct 22.

PMID:
24149079
12.

Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post-pandemic period.

Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B.

Clin Respir J. 2014 Apr;8(2):185-91. doi: 10.1111/crj.12056. Epub 2013 Nov 26.

13.

Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.

Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.

PLoS One. 2013 Aug 16;8(8):e70866. doi: 10.1371/journal.pone.0070866. eCollection 2013.

14.

Measuring antibody responses to a live attenuated influenza vaccine in children.

Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM.

Pediatr Infect Dis J. 2004 Sep;23(9):852-6.

PMID:
15361726
15.

Rate of decline of antibody titers to pandemic influenza A (H1N1-2009) by hemagglutination inhibition and virus microneutralization assays in a cohort of seroconverting adults in Singapore.

Hsu JP, Zhao X, Chen MI, Cook AR, Lee V, Lim WY, Tan L, Barr IG, Jiang L, Tan CL, Phoon MC, Cui L, Lin R, Leo YS, Chow VT.

BMC Infect Dis. 2014 Jul 28;14:414. doi: 10.1186/1471-2334-14-414.

16.

Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan.

Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, Shobugawa Y, Saito R, Suzuki H; Japanese Influenza Collaborative Study Group.

PLoS One. 2012;7(6):e36455. doi: 10.1371/journal.pone.0036455. Epub 2012 Jun 27.

17.

A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.

Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.

Hum Vaccin Immunother. 2015;11(10):2370-5. doi: 10.1080/21645515.2015.1064570.

18.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13.

PMID:
25513756
19.

Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.

Camilloni B, Basileo M, Menculini G, Tozzi P, Iorio AM.

Adv Exp Med Biol. 2016;897:45-53. doi: 10.1007/5584_2015_5003.

PMID:
26577530
20.

Factors associated with maintenance of antibody responses to influenza vaccine in older, community-dwelling adults.

Talbot HK, Coleman LA, Zhu Y, Spencer S, Thompson M, Cheng PY, Sundaram ME, Belongia EA, Griffin MR.

BMC Infect Dis. 2015 Apr 23;15:195. doi: 10.1186/s12879-015-0926-8.

Supplemental Content

Support Center